Phase I dose-escalating trial of hepcidin [LJPC-401] in patients at risk of iron overload
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2016
At a glance
- Drugs Hepcidin (Primary)
- Indications Iron overload
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors La Jolla Pharmaceutical Company
- 07 Sep 2016 Results published in La Jolla media release.
- 08 Aug 2016 According to La Jolla media release, company plan to report results in September 2016
- 06 May 2016 According to a La Jolla Pharmaceutical media release, complete results from this trial are expected in the second half of 2016.